Related Experiment Video
Updated: May 13, 2026
Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration
Published on: June 9, 2023
Ani-survivin DNAzymes inhibit cell proliferation and migration in breast cancer cell line MCF-7
Abstract:
Survivin, a new member of the inhibitor of apoptosis protein (IAP) family, both inhibits apoptosis and regulates the cell cycle. It is overexpressed in breast tumor tissues. In this study, we designed two survivin specific DNAzymes (DRz1 and DRz2) targeting survivin mRNA. The results showed that DRz1 could decrease the expression of survivin by nearly 60%. Furthermore, DRz1 significantly inhibited cell proliferation, induced apoptosis and inhibited migration in MCF-7 cells. In addition, down-regulation of survivin expression was associated with increased caspase-3 and -9 activities in MCF-7 cells after 24 h transfection. In our experiments, the efficacy of DRz1 to influence survivin levels and associated effects were better than DRz2. Survivin-DRz1 might have anti-tumorigenic activity and may potentially provide the basis for a novel therapeutic intervention in breast cancer treatment.
Insights
This study developed DNAzymes to target survivin, a protein overexpressed in breast cancer. Survivin-DRz1 effectively reduced survivin levels, inhibiting cancer cell growth and promoting apoptosis.
Area of Science:
- Molecular Biology
- Cancer Research
- Biochemistry
Background:
- Survivin, an inhibitor of apoptosis protein (IAP) family member, is overexpressed in breast tumors.
- Survivin plays a critical role in inhibiting apoptosis and regulating cell cycle progression.
Purpose of the Study:
- To design and evaluate survivin-specific DNAzymes for targeting survivin mRNA.
- To assess the anti-tumorigenic potential of these DNAzymes in breast cancer cells.
Main Methods:
- Design of two survivin-specific DNAzymes (DRz1 and DRz2).
- Transfection of MCF-7 cells with DNAzymes.
- Assessment of survivin expression levels via quantitative analysis.
- Evaluation of cell proliferation, apoptosis, migration, and caspase activity.
Main Results:
- DRz1 significantly decreased survivin expression by nearly 60%.
- DRz1 inhibited MCF-7 cell proliferation and migration, while inducing apoptosis.
- Down-regulation of survivin by DRz1 correlated with increased caspase-3 and -9 activities.
- DRz1 demonstrated superior efficacy compared to DRz2.
Conclusions:
- Survivin-DRz1 exhibits significant anti-tumorigenic activity in vitro.
- Survivin-DRz1 holds potential as a novel therapeutic strategy for breast cancer treatment.
